These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 25937270

  • 41. Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Takamori S, Toyokawa G, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.
    Anticancer Res; 2017 Aug; 37(8):4223-4228. PubMed ID: 28739710
    [Abstract] [Full Text] [Related]

  • 42. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A, Siegel L, Freese R, Racila E, Stewart J, Amin K.
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [Abstract] [Full Text] [Related]

  • 43. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL, Yang CY, Lin MW, Wu CT, Yang PC.
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [Abstract] [Full Text] [Related]

  • 44. Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer.
    Zhao L, Chen P, Fu K, Li J, Dai Y, Wang Y, Zhuang Y, Sun L, Chen H, Lin Q.
    Front Oncol; 2020 Jun; 10():551367. PubMed ID: 33708615
    [Abstract] [Full Text] [Related]

  • 45. Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms.
    Matsumoto K, Ohara T, Fujisawa M, Takaki A, Takahara M, Kato H, Yoshida R, Umeda Y, Yagi T, Matsukawa A, Okada H.
    J Gastrointest Surg; 2022 Jun; 26(6):1213-1223. PubMed ID: 35137343
    [Abstract] [Full Text] [Related]

  • 46. Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray.
    Elfving H, Mattsson JSM, Lindskog C, Backman M, Menzel U, Micke P.
    Clin Lung Cancer; 2019 Jul; 20(4):258-262.e1. PubMed ID: 30926355
    [Abstract] [Full Text] [Related]

  • 47. Correlation of programmed death-ligand 1 expression in tumour cells between diagnostic small biopsies performed by radial EBUS and surgical specimens of peripheral lung cancer.
    Lachkar S, Gervereau D, Loïc P, De Marchi M, Morisse H, Dantoing E, Piton N, Thiberville L, Salaün M, Guisier F.
    BMJ Open Respir Res; 2024 Oct 15; 11(1):. PubMed ID: 39414327
    [Abstract] [Full Text] [Related]

  • 48. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Haratake N, Toyokawa G, Tagawa T, Kozuma Y, Matsubara T, Takamori S, Akamine T, Yamada Y, Oda Y, Maehara Y.
    Anticancer Res; 2017 Oct 15; 37(10):5713-5717. PubMed ID: 28982891
    [Abstract] [Full Text] [Related]

  • 49. Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
    Biswas A, Leon ME, Drew P, Fernandez-Bussy S, Furtado LV, Jantz MA, Mehta HJ.
    Diagn Cytopathol; 2018 May 15; 46(5):378-383. PubMed ID: 29476608
    [Abstract] [Full Text] [Related]

  • 50. Comparison of the yield of different diagnostic procedures for cellular differentiation and genetic profiling of non-small-cell lung cancer.
    Albanna AS, Kasymjanova G, Robitaille C, Cohen V, Brandao G, Pepe C, Small D, Agulnik J.
    J Thorac Oncol; 2014 Aug 15; 9(8):1120-5. PubMed ID: 25157765
    [Abstract] [Full Text] [Related]

  • 51. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
    Jain D, Sukumar S, Mohan A, Iyer VK.
    Cytopathology; 2018 Dec 15; 29(6):550-557. PubMed ID: 29938855
    [Abstract] [Full Text] [Related]

  • 52. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle.
    Cheung YC, Chang JW, Hsieh JJ, Lin G, Tsai YH.
    Lung Cancer; 2010 Feb 15; 67(2):166-9. PubMed ID: 19450892
    [Abstract] [Full Text] [Related]

  • 53. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Han JJ, Kim DW, Koh J, Keam B, Kim TM, Jeon YK, Lee SH, Chung DH, Heo DS.
    Clin Lung Cancer; 2016 Jul 15; 17(4):263-270.e2. PubMed ID: 26707383
    [Abstract] [Full Text] [Related]

  • 54. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
    Tsai EB, Pomykala K, Ruchalski K, Genshaft S, Abtin F, Gutierrez A, Kim HJ, Li A, Adame C, Jalalian A, Wolf B, Garon EB, Goldman JW, Suh R.
    Radiology; 2018 Apr 15; 287(1):326-332. PubMed ID: 29232184
    [Abstract] [Full Text] [Related]

  • 55. The Macroscopic Appearance of Computed Tomography-guided Needle Biopsy Specimens Correlates with Tumor Metastasis in Non-small Cell Lung Cancer.
    Toshiyuki N, Kimura T, Suzumura T, Yoshimoto N, Oka T, Yamamoto N, Matsuura K, Mitsuoka S, Asai K, Tochino Y, Yoshimura N, Kawaguchi T, Kudoh S, Matsuoka T, Ohsawa M, Hirata K.
    Osaka City Med J; 2015 Dec 15; 61(2):105-12. PubMed ID: 26995854
    [Abstract] [Full Text] [Related]

  • 56. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
    Grosu HB, Arriola A, Stewart J, Ma J, Bassett R, Hernandez M, Ost D, Roy-Chowdhuri S.
    Respirology; 2019 Dec 15; 24(12):1198-1203. PubMed ID: 31209954
    [Abstract] [Full Text] [Related]

  • 57. Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.
    Munari E, Zamboni G, Sighele G, Marconi M, Sommaggio M, Lunardi G, Rossi G, Cavazza A, Moretta F, Gilioli E, Caliò A, Netto GJ, Hoque MO, Martignoni G, Brunelli M, Vacca P, Moretta L, Bogina G.
    Cancer Cytopathol; 2019 Feb 15; 127(1):52-61. PubMed ID: 30500997
    [Abstract] [Full Text] [Related]

  • 58. Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer.
    Matsumoto T, Hasebe T, Baba Y, Chosa K, Kondo S, Yamada S, Yoshimatsu R, Kubota T, Fujitaka K, Awai K, Yamagami T.
    Anticancer Res; 2018 Jun 15; 38(6):3587-3592. PubMed ID: 29848714
    [Abstract] [Full Text] [Related]

  • 59. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.
    Eur J Cancer; 2015 Nov 15; 51(17):2698-707. PubMed ID: 26329973
    [Abstract] [Full Text] [Related]

  • 60. Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients.
    Otani H, Toyooka S, Soh J, Yamamoto H, Suehisa H, Kobayashi N, Gobara H, Mimura H, Kiura K, Sano Y, Kanazawa S, Date H.
    J Thorac Oncol; 2008 May 15; 3(5):472-6. PubMed ID: 18448998
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.